questionText: To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the introduction of teplizumab contributes to reducing rates of diabetic ketoacidosis at diagnosis and inequalities in outcomes for people with type 1 diabetes.
answerText: Teplizumab is a new treatment for people aged eight years old and over with stage 2 type 1 diabetes, before the onset of symptoms. Its introduction represents a significant development in the treatment of type 1 diabetes and requires new clinical pathways...
heading: Teplizumab